Website
News25/Ratings0
News · 26 weeks32-100%
2025-10-262026-04-19
Mix790d
- SEC Filings3(43%)
- Market2(29%)
- Other1(14%)
- Insider1(14%)
Latest news
25 items- NEWSenVVeno Medical Reports Full Year 2025 Financial Results and Highlights Strategic Advancement of enVVe(R) SystemCompany accelerated development of the enVVe® System, completing pre-clinical studies and progressing toward a 2026 pivotal trial initiationStrong financial position expected to provide an operating runway into mid-2027 through the achievement of key clinical milestonesIRVINE, CA / ACCESS Newswire / March 27, 2026 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno Medical" or the "Company"), today announced financial results for the year ended December 31, 2025 and provided a corporate update highlighting its strategic focus on the development of its next-generation enVVe® System.Robert Berman, Chief Executive Officer of enVVeno Medical Corporation, stated, "2025 represented a significant
- SECSEC Form S-8 filed by enVVeno Medical CorporationS-8 - enVVeno Medical Corp (0001661053) (Filer)
- SECSEC Form 10-K filed by enVVeno Medical Corporation10-K - enVVeno Medical Corp (0001661053) (Filer)
- INSIDERDirector Duhay Francis sold $1,613 worth of shares (140 units at $11.52), decreasing direct ownership by 5% to 2,502 units (SEC Form 4)4 - enVVeno Medical Corp (0001661053) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by enVVeno Medical CorporationSCHEDULE 13G/A - enVVeno Medical Corp (0001661053) (Subject)
- SECenVVeno Medical Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits8-K - enVVeno Medical Corp (0001661053) (Filer)
- NEWSenVVeno Medical Regains Compliance with Nasdaq Minimum Bid Price RequirementCompany achieves minimum $1.00 closing bid for 10 consecutive business days; Nasdaq confirms matter is closedReports Cash and Investments of approximately $28 million as of the Year Ended December 31, 2025IRVINE, CA / ACCESS Newswire / February 4, 2026 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno Medical" or the "Company"), today announced that it has received formal notice from the Listings Qualifications staff of The Nasdaq Stock Market LLC ("Nasdaq") that the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share. Nasdaq confirmed that for the last 10 consecutive business days, from January 20, 2026 through Febru
- SECenVVeno Medical Corporation filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year8-K - enVVeno Medical Corp (0001661053) (Filer)
- NEWSenVVeno Medical Announces Reverse Stock SplitIRVINE, CA / ACCESS Newswire / January 15, 2026 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno Medical" or the "Company"), today announced that the Company's Board of Directors has approved a reverse stock split of its shares of common stock at a ratio of 1 for 35 (the "Reverse Stock Split"). The Reverse Stock Split will become effective at 12:01 a.m. Eastern time on January 20, 2026 and the Company's common stock will open for trading on The Nasdaq Capital Market on a post-split basis on January 20, 2026 under the Company's existing trading symbol "NVNO". At such time, the Company's common stock will also commence trading under a new CUSIP number 29415J205."The Reverse Stock Split, w
- INSIDERSEC Form 4 filed by Chief Executive Officer Berman Robert Andrew4 - enVVeno Medical Corp (0001661053) (Issuer)
- INSIDERSEC Form 4 filed by Chief Technology Officer Alavi Hamed4 - enVVeno Medical Corp (0001661053) (Issuer)
- INSIDERSEC Form 4 filed by SVP & Chief Medical Officer Glickman Marc H.4 - enVVeno Medical Corp (0001661053) (Issuer)
- INSIDERSEC Form 4 filed by Director Duhay Francis4 - enVVeno Medical Corp (0001661053) (Issuer)
- INSIDERSEC Form 4 filed by Director Gray Robert4 - enVVeno Medical Corp (0001661053) (Issuer)
- INSIDERSEC Form 4 filed by Director Jenusaitis Matthew4 - enVVeno Medical Corp (0001661053) (Issuer)
- INSIDERSEC Form 4 filed by Director Shrivastava Sanjay4 - enVVeno Medical Corp (0001661053) (Issuer)
- INSIDERDirector Duhay Francis sold $1,742 worth of shares (4,900 units at $0.36), decreasing direct ownership by 5% to 92,544 units (SEC Form 4)4 - enVVeno Medical Corp (0001661053) (Issuer)
- SECenVVeno Medical Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - enVVeno Medical Corp (0001661053) (Filer)
- SECSEC Form DEFR14A filed by enVVeno Medical CorporationDEFR14A - enVVeno Medical Corp (0001661053) (Filer)
- NEWSenVVeno Medical (NASDAQ:NVNO) to Participate in a Live Virtual Investor CEO Connect SegmentModerated webcast with Robert Berman, Chief Executive Officer of enVVeno Medical on Wednesday, December 3rd at 4:00 PM ET IRVINE, CA / ACCESS Newswire / November 26, 2025 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno Medical" or the "Company"), today announced that Robert Berman, Chief Executive Officer of enVVeno Medical will participate in a Live Virtual Investor CEO Connect segment on Wednesday, December 3, 2025 at 4:00 PM ET.As part of the event, Mr. Berman will provide a corporate overview and discuss the Company's recent news and next steps. In addition to the moderated discussion, there will be a live question and answer session. Mr. Berman will answer as many questions as pos
- SECenVVeno Medical Corporation filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits8-K - enVVeno Medical Corp (0001661053) (Filer)
- SECSEC Form PRER14A filed by enVVeno Medical CorporationPRER14A - enVVeno Medical Corp (0001661053) (Filer)
- SECSEC Form SCHEDULE 13G filed by enVVeno Medical CorporationSCHEDULE 13G - enVVeno Medical Corp (0001661053) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by enVVeno Medical CorporationSCHEDULE 13G/A - enVVeno Medical Corp (0001661053) (Subject)
- SECenVVeno Medical Corporation filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - enVVeno Medical Corp (0001661053) (Filer)